The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
No Consensus on PMP Company Criteria, Likely Review for Spillover Rule: Chuikyo
Japan’s health ministry on November 29 proposed specific policy directions for each of all topics that have been raised towards the FY2024 drug pricing reform. While its proposal signals its eagerness to tackle the issue of drug lags and losses,…
To read the full story
Related Article
- Chuikyo Agrees to Scrap Company Indicators to Rank PMP-Eligible Firms
December 14, 2023
- Pharma Industry Backs MHLW Proposal to Scrap PMP Indicators: Chuikyo Hearing
December 7, 2023
- MHLW Proposes Tightening 40% Entry Pricing for New Oral Generics
November 30, 2023
- MHLW Pushes Boosted Launch Premiums, Slew of Other Pricing Steps to Reward Innovation
November 30, 2023
- Chuikyo Reps Split on Nixing PMP Company Criteria; Many Back Review of Reduction Caps under Re-Pricing
November 24, 2023
- Chuikyo at Odds over Handling of Startups in PMP, Timing of Deferred Price Cuts
October 19, 2023
REGULATORY
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
- LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
- LDP’s Patch League Urges Finance Minister to Continue Coverage, Support Prices
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…